- Home
- BIOA vs CADL Comparison
BIOA vs CADL Comparison
Compare BIOA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | CADL |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 339.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BIOA | CADL |
|---|---|---|
| Price | $13.18 | $5.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $13.50 | ★ $19.43 |
| AVG Volume (30 Days) | 485.8K | ★ 971.2K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $4.25 |
| 52 Week High | $14.46 | $13.68 |
Technical Indicators
Market Signals| Indicator | BIOA | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 65.18 | 51.59 |
| Support Level | $13.52 | $5.45 |
| Resistance Level | $14.46 | $6.14 |
| Average True Range (ATR) | 0.69 | 0.38 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 49.59 | 13.09 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.